论文信息 - Reply to J. Wang et al. - 字舞流文

Reply to J. Wang et al.

Ash A. Alizadeh | Aaron M. Newman | R. Tibshirani | A. Newman | W. Wilson | R. Advani | C. Liu | J. Chabon | D. Kurtz | M. S. Esfahani | H. Stehr | M. Jin | M. Diehn | O. Casasnovas | D. Rossi | G. Gaidano | A. Hüttmann | U. Dührsen | M. Meignan | L. Maeda | M. Khodadoust | J. Westin | F. Scherer | M. Roschewski | N. Gupta | A. Craig | Joanne Soo

[1] Stefan Sleijfer,et al. Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions , 2017, Molecular oncology.

[2] R. Gascoyne,et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.

[3] Jill P. Mesirov,et al. Criteria for the use of omics-based predictors in clinical trials , 2013, Nature.

[4] H. Tschan,et al. Increased concentrations of cell-free plasma DNA after exhaustive exercise. , 2004, Clinical chemistry.

[5] Y. Lo,et al. Time course of early and late changes in plasma DNA in trauma patients. , 2003, Clinical chemistry.

[6] M. Busch,et al. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma , 2001, Transfusion.